Study to Evaluate the Safety, Pharmacokinetics and Tolerability of BMS-708163

Summary

The primary objective is to assess the safety and tolerability of a single oral dose of BMS-708163 in healthy young male subjects and in elderly male and female subjects.

Conditions

• Alzheimer's Disease

Interventions

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 0.3 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 1.5 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 5.0 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 15.0 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 50 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 100 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 200 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 400 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Capsule, Oral, 50 mg, Once daily, once

DRUG

BMS-708163 (Gamma-Secretase Inhibitor)

Oral Solution, Oral, 800 mg, Once daily, once

DRUG

Placebo matching BMS-708163

Oral Solution, Oral, 0 mg, Once daily, once

DRUG

Placebo matching BMS-708163

Capsule, Oral, 0 mg, Once daily, once

Sponsors & Collaborators

• Bristol-Myers Squibb

  lead INDUSTRY

Principal Investigators

• Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2007-06-30

Primary Completion

2009-03-31

Completion

2009-03-31